What We Treat

At the Aflac Cancer and Blood Disorders Center, our team is highly skilled and experienced in treating children and young adults with all forms of childhood cancer and blood disorders—from the most common to those rarely seen outside of the top pediatric centers. We treat:

Cancers

Blood disorders

  • Hemophilia
  • Thrombosis
  • Other coagulation and bleeding disorders
  • Sickle cell disease
  • Thalassemia
  • Bone marrow failure syndromes
  • Other red blood cell disorders, including acute and chronic anemia
  • White blood cell disorders

Services We Offer

Comprehensive programs

  • Cancer Program: We are home to one of the top childhood cancer centers in the country. We have doctors who are skilled in treating all forms of cancer, including leukemia, lymphoma, brain tumors and solid tumors. Our cancer survivor program helps survivors and their families get the help and resources they need.
  • Blood Disorders Program: We care for more than 2,500 children with sickle cell disease, hemophilia and other blood disorders each year. This includes more than 1,700 children with sickle cell—making us the largest pediatric sickle cell program in the country.
  • Blood and Marrow Transplant Program: As one of the top pediatric BMT programs in the country, we provide expertise in autologous and allogeneic transplants. We are a national leader in transplanting children with sickle cell disease—we have cured more than 55 children.
  • Developmental Therapeutics Program: Our team focuses on the discovery and creation of new treatments for children with cancer and blood disorders. Our goal is to provide every opportunity for a child to be cured of his disease.

Innovative research

The Aflac Cancer Center is committed to excellence and innovation in pediatric cancer and blood disorders research. We are home to one of the largest clinical trial programs in the country—offering our patients access to some of the most novel treatment options in the country.

Find a clinical trial

Clinical trial highlights

Sidonio named PI on upcoming VWD trial

Robert Sidonio Jr., MD, Clinical Director of Hemostasis/Thrombosis with the Emory University School of Medicine, will be the principle investigator for the American Thrombosis and Hemostasis Network von Willebrand disease (VWD) trial called "A Real-World Safety and Efficacy Study of Symptomatic VWD." The study begins in the third quarter of 2017 and is funded by Shire, a global innovator in specialty biopharmaceuticals. Dr. Sidonio's PI is Angela Weyland, MD, from the University of Michigan.

This $2.5 million award will seek to characterize children and adults with VWD in the United States and focus on characterization of the bleeding symptoms of those VWD patients with symptomatic disease, requiring medical intervention on a regular basis. The study will focus on certain populations, such as adolescent girls and women with VWD, as they comprise nearly 80 percent of all medical claims, according to a recent medical claims study.

The study will also seek to further understand the different types of VWD and the severity of bleeding symptoms. It will provide the framework to answer future questions regarding why some patients have worse bleeding than others, while also documenting successful strategies in treatment, including factor replacement.

Dr. Sidonio hopes that this project will jump-start additional studies in VWD using the ATHNdataset, including but not limited to long-term effects of angiodysplasia in VWD, aging in VWD, cardiovascular effects from VWD and changes in levels of VWD over time.

VWD is the most common bleeding disorder in humans. It affects approximately 1 in 1,000 people in the United States. There have been more than 7,000 patients with VWD described as part of the ATHNdataset.

Wetmore named PI on new first-in-pediatrics study

Cynthia Wetmore, MD, PhD, Director of the Development Therapeutics Program at Aflac Cancer and Blood Disorders Center, is the principal investigator on a new first-in-pediatrics study involving abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (Cdk 4/6) for children with newly diagnosed diffuse pontine glioma and for patients with recurrent or progressive solid tumors, including malignant brain tumors. Dr. Wetmore holds the Carter Samuel Martin endowed chair in developmental therapeutics and this new study is generously supported by the CURE Childhood Cancer Foundation and Eli Lilly Pharmaceuticals.

Abemaciclib is taken as a pill twice a day and is a small molecule inhibitor of Cdk 4/6, which is an important enzyme regulating progression through the cell cycle and cell division. Inhibition of this kinase is particularly damaging to tumor cells, which are often not able to recover from such a blockade. Unlike other inhibitors of Cdk 4/6, this agent is readily able to cross the blood brain barrier, making it a very attractive option for brain tumors that are resistant to other types of therapy. This class of inhibitors has been approved by the Federal Drug Administration (FDA) for use in certain types of breast cancer, but this is the first study to include pediatric patients.

In addition to developing our own approach, we are participating in the ongoing CTL-019 (Novartis) trial and are a referral center.


Our Unique Approach

The Aflac Cancer and Blood Disorders Center is one of the leading childhood cancer and blood disorders programs in the country. Combining the latest proven technology and research with a caring, child-friendly approach, makes the Aflac Cancer Center a top choice for the treatment of common and complex cancer and blood disorder conditions.

Learn more about what makes Children's special


Meet the Team

Meet our Cancer and Blood Disorders team

Helpful Resources

New patient forms

Request a new patient appointment

Before your visit

Learn how to prepare for your visit to the Aflac Cancer Center, including information about our transitional housing options for families traveling from outside of Atlanta.

Get information and tips

Camps, events and support groups

Camps, retreats and other events offer many therapeutic benefits for children and families who are dealing with serious illness.

Camps, events and support groups

Second opinions and international services

We understand you want to be certain your child is receiving the best possible treatment available anywhere in the world. Second opinions can help provide the information you need to make an informed decision about the treatment for your child. For families traveling outside the U.S., we are here to help meet your unique needs and challenges.

Learn more about our second opinion services

Learn more about our international services

Donate

Learn how you can help make a difference in the life of a child battling cancer or a blood disorder.

Join the fight against childhood cancer and blood disorders

Learn more about how Aflac supports us

Locations

Egleston hospital

1405 Clifton Road NE

Atlanta, GA 30322

Hughes Spalding hospital

35 Jesse Hill Jr. Drive SE

Atlanta, GA 30303

Scottish Rite hospital

1001 Johnson Ferry Road NE

Atlanta, GA 30342-1605

Children's Medical Office Building at Scottish Rite hospital

5461 Meridian Mark Road NE

Atlanta, GA 30342-1654